CD103 blockade impair anti-CTLA-4 immunotherapy in oral cancer

Yao Xiao,Liang Mao,Qi-Chao Yang,Shuo Wang,Zhi-Zhong Wu,Shu-Cheng Wan,Meng-Jie Zhang,Zhi-Jun Sun
DOI: https://doi.org/10.1016/j.oraloncology.2023.106331
IF: 5.972
2023-02-09
Oral Oncology
Abstract:Objectives CD103 + CD8 + T cells is a subtype of T cells with excellent tumor killing ability and it could response to immune checkpoint blockade therapy in several types of cancer, but the phenotype, role and molecular mechanism CD103 + CD8 + T cells in the OSCC still unclear. Materials and methods The distribution and phenotype of CD103 + CD8 + T cells were investigated by performing multiplexed immunohistochemistry on human OSCC tissue microarray and flow cytometric analysis of fresh OSCC tumor-infiltrating lymphocytes (TILs). By in vivo use of anti-CD103 monoclonal antibody (mAb) in the 4MOSC1 tumor-bearing mouse model, CD103 + CD8 + T cell infiltration and cytotoxicity was clarified. Results The majority of CD8 + T cells in both human and animal OSCC intra-tumoral region were CD103 + CD8 + T cells with high expression levels of cytotoxic molecules, which can be impaired by CD103 blockade. In addition, combined use of anti-CD103 mAb with anti-CTLA-4 mAb displayed impaired immune checkpoint blockade therapy efficiency. Conclusion CD103 + CD8 + T cells are the major intra-tumoral subset of CD8 + T cells in both animal and human OSCC, and that CD103 + CD8 + T cells demonstrate remarkable tumor-infiltrating and tumor-killing properties, thereby CD103 + CD8 + T cells may critical for anti-CTLA-4 immunotherapy in OSCC.
dentistry, oral surgery & medicine,oncology
What problem does this paper attempt to address?